Following chemotherapy, among surviving AML cells, there was a significant reduction in the proportion of cells with either an LSC immunophenotype (CD34+CD38−) or a progenitor immunophenotype (Figs. 3B-C). This evidence concerns the gene CD34 and acute myeloid leukemia.